Lava Therapeutics reports Q4 EPS (24c), consensus (12c)

Reports Q4 revenue $199,000, consensus $6.25M. “In 2023, we advanced our portfolio of proprietary Gammabody programs. LAVA-1207 has enrolled dose level 9 in our Phase 1/2a trial of patients with metastatic castration-resistant prostate cancer. We will soon be enrolling the patients in our pembrolizumab combination arm. We continue to be encouraged by the favorable safety profile and preliminary signs of anti-tumor activity. We plan to provide new data for LAVA-1207 at an upcoming medical conference in the second half of 2024,” said Stephen Hurly, President and Chief Executive Officer of LAVA. “We are also very excited by Pfizer’s clinical progress. They have been a great partner and we look forward to continuing to support them. We plan to submit an IND for LAVA-1266, our investigational asset designed to target CD123 for the treatment of acute myeloid leukemia and myelodysplastic syndromes, in Q2 2024,” continued Mr. Hurly. “These advances represent important steps for our proprietary Gammabody T-cell engagers as we evaluate their potential to treat cancer. We believe that 2024 will be a significant year and we look forward to sharing our ongoing progress with investors and stakeholders.”